Ming-Sound Tsao, MD, FRCPC

Translational Research in Lung and Pancreatic Cancer.
Lung and pancreatic cancers are the two most deadly cancers with overall five-year survival rates of 15% and 2-5%. Understanding the molecular basis of their malignancy will provide insights for improving the early diagnosis and treatment of these diseases.

Our primary goal in lung cancer research is to identify genes or proteins that are predictive of poor prognosis in lung cancer patients who have had their tumors resected by surgery.

In the laboratory, we use lung cancer cell lines as in vitro models, snap-frozen and paraffin embedded human lung cancer tissues as primary tumor model, and orthotopic implantation of lung cancer cells in immune deficient mice as in vivo model to evaluate the biology and metastatic potential of lung cancer cells. Clinical tissue samples are used to identify tumor-associated mutations, gene expression changes and gene copy number aberrations that correlate with poor clinical outcome. Additional studies are performed on cell lines with different metastatic potential.

Candidate prognostic genes are identified using high throughput and genome wide microarray techniques. Validation of their prognostic significance in large cohorts of cancer samples is performed using high throughput realtime RT-PCR and tissue microarray techniques.

The mechanisms that these genetic aberrations may affect the biology of lung cancer cells are then studied using in vitro cell line models and in vivo orthotopic metastatic lung cancer model.

Prognostic genes are potential target for the development of new anti-cancer drugs. Special interests and emphasis are on ras oncogene and Hepatocyte Growth Factor (HGF) and its receptor Met tyrosine kinase receptor.

HGF-Met interaction plays important role in the growth, movement and differentiation of normal and tumor cells. Because of its activity on cell motility, HGF is thought to be important in tumor cell invasion and metastasis. The laboratory continues to study the autocrine and paracrine roles of this growth loop in modulating the growth, differentiation and metastasis of lung cancer cells.

Additional studies focus on discovering biomarkers that can predict response to newly developed targeted anticancer drugs, such as inhibitors of the epidermal growth factor receptor.

The laboratory is also actively studying the molecular basis of multi-stage development of human pancreatic cancer. A majority of pancreatic cancers arise from duct epithelium, and the latter may also differentiate into islet cells. This suggests the potential 'stem-cell' nature of pancreatic duct cells.

My laboratory was the first one to establish primary cultures of normal duct cells from adult human pancreas, and immortalized cell lines derived from these normal duct cells. Clones of immortal cell lines were isolated and they showed near normal genotype and phenotype. These cells are being used as in vitro models to study the role of oncogenes and tumor suppressor genes in the malignant transformation of pancreatic duct cells.

The goal of this project is to delineate the biological and molecular mechanisms that are critical for transforming normal pancreatic duct cells into pancreatic cancer cells. Knowledge derived from this study will be used to develop markers for early detection of pancreatic cancer, as well as provide insights on developing novel strategies to prevent and treat pancreatic cancer.
Mod Pathol. 2019 Aug 02;:
Churg A, Galateau-Salle F, Roden AC, Attanoos R, von der Thusen JH, Tsao MS, Chang N, De Perrot M, Dacic S
Cancers (Basel). 2019 Jul 19;11(7):
Wang D, Pham NA, Freeman TM, Raghavan V, Navab R, Chang J, Zhu CQ, Ly D, Tong J, Wouters BG, Pintilie M, Moran MF, Liu G, Shepherd FA, Tsao MS
Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1228-1237
Kachuri L, Helby J, Bojesen SE, Christiani DC, Su L, Wu X, Tardón A, Fernández-Tardón G, Field JK, Davies MP, Chen C, Goodman GE, Shepherd FA, Leighl NB, Tsao MS, Brhane Y, Brown MC, Boyd K, Shepshelovich D, Sun L, Amos CI, Liu G, Hung RJ
J Thorac Oncol. 2019 Jun 28;:
Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield AS
Clin Transl Radiat Oncol. 2019 Jul;17:32-39
Lee SL, Cabanero M, Hyrcza M, Butler M, Liu FF, Hansen A, Huang SH, Tsao MS, Song Y, Lu L, Xu W, Chepeha DB, Goldstein DP, Weinreb I, Bratman SV
Cancer Res. 2019 May 29;:
Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, Tsao MS, Cescon DW, Goldenberg A, Haibe-Kains B
Oncologist. 2019 May 28;:
Melosky B, Juergens R, Hirsh V, McLeod D, Leighl N, Tsao MS, Card PB, Chu Q
Cancers (Basel). 2019 May 22;11(5):
Zeltz C, Pasko E, Cox TR, Navab R, Tsao MS
Neoplasia. 2019 Apr 09;21(5):482-493
Hao J, Zeltz C, Pintilie M, Li Q, Sakashita S, Wang T, Cabanero M, Martins-Filho SN, Wang DY, Pasko E, Venkat K, Joseph J, Raghavan V, Zhu CQ, Wang YH, Moghal N, Tsao MS, Navab R
J Proteome Res. 2019 Apr 12;:
Krieger JR, Wybenga-Groot LE, Tong J, Bache N, Tsao MS, Moran MF

Pages


 


Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto
Professor, Department of Medical Biophysics, University of Toronto